GTU-MultiHIV B clade vaccine

GTU-MultiHIV B clade vaccine is a synthetic DNA-based therapeutic HIV-1 vaccine developed to induce cellular immune responses against HIV-1 subtype B. The vaccine encodes a MultiHIV antigen—a synthetic fusion protein constructed from full-length polypeptides of Rev, Nef, Tat, and Gag p17 and p24 proteins. It also includes more than 20 T-helper (Th) and cytotoxic T lymphocyte (CTL) epitopes derived from protease, reverse transcriptase, and gp160 regions of the HAN2 HIV-1 subtype B strain. The primary mechanism is to stimulate robust CD4+ and CD8+ T-cell responses targeting multiple conserved regions of the virus. The product does not contain live or killed whole virus but instead uses plasmid DNA encoding these antigens. The main indication has been as a therapeutic (not preventive) HIV-1 vaccine in people living with HIV on suppressive antiretroviral therapy (ART), aiming to enhance immune control over viral replication. Clinical trials have shown that it is safe and well-tolerated but has limited efficacy as monotherapy in improving pre-existing immune responses in ART-treated individuals; prime-boost strategies are being explored for greater effect[1][2][3][5][7].

Brand names

GTU-MultiHIV

Other names

GTU®MultiHIV DNA vaccineDNA-GTU-multiHIV B clade vaccine